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Executive 
summary
1. The medical journey travelled by patients with a rare disease (and their families) 
from initial disease recognition or onset of symptoms to a final diagnosis may 
involve serial referrals to several specialists and a plethora of, often invasive, tests. 
This odyssey can be prolonged and, as a result, have serious consequences for 
the health of patients. 
2. Measuring diagnostic odysseys presents several methodological challenges:
 • the small numbers of people affected means there is only weak statistical power 
to detect changes in the length of odysseys;
 • the low incidence of each disease means that, except for specialist centres, 
collecting data on patients dispersed over a large number of providers is a 
logistical challenge;
 • there is no universally agreed definition of the start and end points of odysseys. 
3. Our aim was to explore whether an accurate, robust and cost-effective method 
can be developed for the routine measurement of rare diseases diagnostic 
odysseys to enable the impact of interventions and policies, such as the 2013 UK 
Strategy for Rare Diseases, to be evaluated.
4. We carried out:
 • a review of 66 studies of 40 rare diseases to establish how the diagnostic 
odyssey has been investigated in the UK and elsewhere; 
 • a review of databases that monitor the time to diagnosis in other conditions that 
can have prolonged diagnostic odysseys (cancers and diabetes); 
 • a review of five categories of databases that offer opportunities to provide 
information about rare diseases diagnostic odysseys: generic hospital 
databases; primary care databases; rare diseases databases; specialist 
department databases; and the recently established National Congenital 
Anomaly & Rare Disease Registration Service;
 • interviews with 22 experts in the field of rare diseases.
5. The diagnostic odyssey comprises three periods of time: patient interval; primary 
care interval; and specialist care interval:
Presentation 
to care
Referral to 
specialist care
Onset of symptoms 
and/or signs
Primary care interval Specialist care interval
Diagnosis
Patient interval
First time the 
patient/parent 
notices what will 
later be classified 
as a symptom or 
sign of the disease
First time the 
patient/parent 
is seen in 
primary care
Time at which 
responsibilty for 
the diagnosis shifts 
to specialist care
Time at which 
diagnosis is made
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6. We recommend that:
 • monitoring of the odyssey should be retrospective in design and focus on a 
‘basket’ of tracer diseases; 
 • primary care data should form the foundation initially restricted to data from 
primary care research databases;
 • the foundation provided by primary care data should be enhanced and 
validated by the addition of data from three other sources: rare diseases 
databases; specialist department databases; and patient/parent surveys;
 • these proposals should be subject to widespread consultation among all 
those with an interest in and expert knowledge of the clinical, diagnostic and 
management of the conditions; 
 • whatever course of action is subsequently decided upon will need to be 
rigorously tested in pilot studies of two or three rare diseases.
The policy adopted will need to be reviewed in the light of two promising prospects: 
the availability of the General Practice Extraction Service and the National Congenital 
Anomaly & Rare Disease Registration Service. These may provide better options for 
monitoring the diagnostic odyssey than the short-term solutions being proposed.
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1.1 Background
The medical journey travelled by patients with a rare disease (and their families) from 
initial disease recognition or onset of symptoms to a final diagnosis may involve serial 
referrals to several specialists and a plethora of, often invasive, tests. This odyssey can 
be prolonged and, as a result, have serious consequences for the health of patients. 
A 2004 European survey of the time between identification of early symptoms and a 
final diagnosis for a subset of rare diseases (Crohn’s disease, Cystic fibrosis, Duchenne 
muscular dystrophy, Ehlers-Danlos syndrome, Marfan syndrome, Prader Willi syndrome, 
Tuberous sclerosis, Fragile X syndrome) reported 25% of patients had to wait between 
5 and 30 years [1]. During the odyssey people may receive sub-optimal care and 
support, which will also have adverse resource implications for the health service [2].
A rare disease is a life-threatening or chronically debilitating disease that affects five 
people or fewer in 10,000 and requires special, combined efforts to enable patients to 
be treated effectively. The total number of rare diseases is steadily increasing (current 
estimates suggest 5000 to 8000) because genetic research is beginning to explain 
disease patterns that were not understood before. Research suggests that one in 17 
people may suffer from a rare disease at some point in their lifetime. In the UK, this 
means that more than 3 million people may have a rare disease. At least 80% of rare 
diseases have an identified genetic origin and 50% of new cases are in children. 
Measuring diagnostic odysseys presents several methodological challenges:
 • the small numbers of people affected means there is only weak statistical power to 
detect changes in the length of odysseys;
 • the low incidence of each disease means that, except for specialist centres, 
collecting data on patients dispersed over a large number of providers is a logistical 
challenge;
 • there is no universally agreed definition of the start and end points of odysseys. 
Several options have been proposed and adopted:
Depending on the particular condition and each person’s particular experiences with 
that condition, a diagnostic odyssey may be conceptualised as beginning when the 
affected person first became symptomatic or at each stage of the health service 
pathway necessary in order for a diagnosis to be possible. 
The end of the diagnostic odyssey for conditions that have an easily accessible, highly 
specific laboratory test is often clearly defined. However for some conditions, early 
laboratory results may be suggestive – but not definitive – of a diagnosis of a rare disease. 
Other conditions can only be diagnosed clinically by an appropriately experienced 
clinician. For such conditions the point at which a differential diagnosis becomes a 
1. Introduction 
Starting point
Initial symptoms/concern raised by patient or parent
Presentation to primary care
Presentation to secondary care
End point
Clinical diagnosis 
Laboratory results suggestive of diagnosis
Laboratory results confirm diagnosis
Condition-specific management started
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confirmed diagnosis is unclear; it may therefore also be appropriate to consider a 
diagnostic odyssey to have ended once a specific management plan is commenced. 
The 2013 UK Strategy for Rare Diseases [2] seeks to address, amongst other issues, 
the delay in diagnosis and, hence the delay in timely and appropriate intervention. 
In order to assess the effectiveness of the UK strategy for rare diseases and the 
associated actions, it would be helpful to explore whether a monitoring system might 
be established that provides some measure or indicator of any improvement in the 
diagnosis of rare diseases to shorten the duration of the diagnostic odyssey. 
Consistent with the notion of ‘rare’ diseases used by the UK Strategy and the 
underlying concerns about prolonged diagnostic odysseys, this project does not 
consider several categories of rarely occurring diseases: 
 • cancers; 
 • acute conditions including infectious diseases; 
 • congenital anomalies;
 • conditions which are screened for in neonates (in which there is no prolonged 
odyssey. Some neonates will be incorrectly diagnosed as suffering from a rare 
disease – false positives – and subsequently experience a diagnostic odyssey but 
these unfortunate instances are beyond the scope of this report). 
While the focus is on past and current attempts to measure the odyssey for rare 
diseases, any lessons that can be learnt from similar challenges in other clinical areas 
(such as cancers) were explored. 
1.2 Aim 
To explore whether an accurate, robust and cost-effective method can be developed 
for the routine measurement of the rare diseases diagnostic odysseys to enable the 
impact of interventions and policies, such as the 2013 UK Strategy for Rare Diseases, 
to be evaluated.
1.3 Objectives
To carry out a literature review on rare diseases diagnostic odysseys to establish how 
it has been investigated in the UK and elsewhere. 
To consider existing databases that monitor the time to diagnosis in other conditions 
(eg certain cancers). 
To identify existing sources of data on rare diseases that might be used including 
GP-based records, hospital administrative data, and specialist clinical databases and 
registries of rare diseases. To assess the extent to which each database includes 
details about the duration of the pathway to diagnosis, the quality of the data, the 
availability of historic data, and the feasibility of linking data to other databases.
 
To develop a conceptual framework of the diagnostic odyssey for the purposes of 
monitoring. 
To develop options for ways of monitoring the diagnostic odyssey for patients with 
rare diseases and assess against pre-determined criteria. 
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2.1 Systematic review
The aim was to identify and synthesise quantitative research into the diagnostic odyssey 
of long-term, non-communicable rare diseases, with a primary focus on how studies 
have defined, collected and analysed time to diagnosis. The inclusion criteria were:
 • conducted in OECD countries;
 • measured, evaluated or sought to understand time to diagnosis; 
 • investigated one or more non-communicable, chronic rare diseases;
 • reported explicitly defined quantitative measures of time to diagnosis in a population 
of patients with a rare disease. 
Included studies were not limited by language, type of publication or publication date. 
All quantitative study designs were eligible, with the exception of single case studies 
or very small case series, unless this represented the entire population for a given 
disease, as such designs would not assist the aim of this review. In contrast to the 
subsequent phases of this project, the systematic review did include rare diseases 
due to malignancies, congenital anomalies and conditions screened for during the 
neonatal period. 
Medline, Embase and PsychINFO databases were searched using search strategies 
based on the following broad logic:
[rare disease] AND [diagnostic odyssey] AND [quantitative study design] AND 
[OECD country]
Full search strategies for each database are included in Appendix 1 along with the 
full review protocol. Institutional repositories of key organisations concerned with 
rare diseases were also searched, key experts were contacted, and the references 
of identified studies were screened. After removal of duplicate entries, 10% of 
retrieved articles were independently screened (by abstract followed by full text) by 
two members of the review team using EPPI-Reviewer software, with the remainder 
screened by a single reviewer. 
Data were extracted by one reviewer and checked for accuracy by a second. 
Data extracted included: study design; rare disease(s) investigated; population 
sampled including method and sampling frame; definition and operationalization of 
time to diagnosis; data collection and analysis method; findings; conclusions; and 
methodological limitations identified by authors. Full details appear in Appendix 2.
A narrative synthesis was conducted. As the primary aim of the review was to 
synthesise the data collection methods rather than the actual results, no formal 
quality appraisal tool used. Instead, the quality of studies was appraised as part of the 
synthesis and discussion rather than a separate process.
In addition to an overall analysis, it was intended to consider two sub-groups: studies 
using routine data only; and studies measuring time to diagnosis as a continuous 
rather than categorical variable. However, there were only five studies that measured 
time to diagnosis so the latter analysis was not conducted. 
2. Methods 
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2.2 Lessons that can be learnt from databases in other clinical 
areas
The challenge of achieving early diagnosis also exists for several common conditions, 
most notably some cancers and diabetes. Measurement of time to diagnosis in these 
areas is likely to provide lessons for rare diseases. We conducted a rapid review of 
the literature and sought the views of experts to identify significant research that has 
been carried out in cancer and in diabetes. 
Medline and Embase were searched using synonyms for ‘time to diagnosis’ or 
‘diagnostic odyssey’, and MeSH (Medical Subject Heading) terms for the United 
Kingdom, limited to studies published in English from 2008 onwards but not limited 
by disease. Search results were consecutively screened by title, abstract and full text 
by a single reviewer. Data were extracted on the definition of ‘time to diagnosis’, data 
collection method and data analysis method. 
2.3 Review of databases with information on rare diseases in 
England 
Data regarding the diagnostic pathway of patients with rare diseases is included in the 
large amount of information that is generated from daily clinical activity in the English 
NHS. Although not all these data are routinely available, useful data can be extracted 
for ad hoc research studies. There are two principal categories of database: generic 
and disease-specific.
Generic databases
Web searches and interviews with experts identified four sources of generic patient-level 
clinical data routinely collected in England (from all or large samples of the population): 
the Clinical Practice Research Datalink (CPRD, which includes the former General 
Practice Research Database, GPRD); the Health Improvement Network (THIN); the 
QResearch database; and Hospital Episode Statistics (HES). These were investigated 
to assess whether their data would allow a robust measure of the diagnostic odyssey 
for rare diseases. (Two other commercial databases were identified, DIN-Link [3] and 
UK IMS Disease Analyzer [4], but were not considered to be relevant).
The websites for the four databases were reviewed and some users were interviewed. 
In addition, research papers that relied on the databases were identified and reviewed 
to obtain detailed information about: the variables included in the databases (data 
dictionaries); data collection mechanisms; extent of national coverage; opportunities 
to link with other databases; and the completeness and accuracy of the data for 
measuring time to diagnosis.
Disease-specific databases
Several databases exist that collect data about patients with rare diseases. They 
are often referred to as registries. In January 2014 Orphanet published a list of such 
databases across Europe [5]. We reviewed the list and identified 74 (Appendix 3) that 
provide data on England. Some were then excluded for one of the following reasons:
 • conditions where a diagnostic odyssey is unlikely to occur because of the natural 
history, such as obvious or life-threatening conditions presenting at birth;
 • acute diseases and cancers, considering that delay in diagnosis for such 
conditions (which may well be rare in terms of prevalence) represent significantly 
different issues in terms of health services and policy research from those 
investigated in the present study;
Diagnostic odyssey for rare diseases: exploration of potential indicators
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 • conditions that neonates are screened for, the gold-standard intervention to reduce 
time to diagnosis;
 • regional coverage only, so could not provide data for a national indicator (though 
national networks of regional databases were included if they covered much of the 
country).
The websites of the 48 databases were reviewed to assess the information they 
included. This led to a shortlist of databases that would allow the time to diagnosis to 
be determined. We focus on the databases that exist in England (or the UK). Although 
some of these contribute to European databases, reviews of the latter would provide 
no additional information so no attention was paid to the wider European composite 
databases.
2.4 Key informant interviews
Interviews were conducted with a range of experts with an interest in the diagnosis 
and management of rare diseases in the UK, including patients and parents. 
Participants were purposively sampled, to maximise variation in perspectives, from 
the following groups: specialist clinicians who care for people with rare diseases; 
specialist laboratory staff; generalist clinicians who occasionally care for people 
with rare diseases; policymakers and commissioners; and patient organisation 
representatives. Participants were selected to cover a range of rare diseases and 
geographical locations across the UK (Appendix 4). 
The majority of interviews were conducted in-person by one or two members of the 
research team. When preferred by the participant, or a face-to-face meeting was not 
possible, the interview was conducted by telephone or email. 
Interviews were semi-structured, informed by a topic guide (Appendix 5) developed 
iteratively throughout the research, and lasted on average 30 minutes. Notes were 
taken and content analysis performed.
2.5 Develop a conceptual framework of diagnostic odyssey
The interview data and findings of the literature reviews were used to develop a 
conceptual framework. This informed both the criteria used to identify sources of data 
and the appraisal of existing databases. The conceptualisation of diagnostic odyssey 
that was developed was influenced by the Aarhus Statement which addresses 
definitions of milestones and intervals in cancer diagnosis odysseys [6].
2.6 Assess options for monitoring the diagnostic odyssey 
The database options for monitoring the odyssey were assessed against the following 
criteria: 
 • range of rare diseases included;
 • information on diagnostic odyssey: extent to which data are included;
 • representativeness of cases included: extent of selection bias; 
 • accuracy of case recruitment: sensitivity (no false negatives) and specificity (no 
false positives); 
 • data completeness: extent to which missing data might bias findings; 
 • validity of data: on diagnostic odyssey;
Diagnostic odyssey for rare diseases: exploration of potential indicators
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 • credibility: how meaningful the data are to patient/parents and clinicians; 
 • timeliness: how up-to-date the data are; 
 • burden and cost of additional data collection: additional time and expense to 
provide data on diagnostic odyssey.
Diagnostic odyssey for rare diseases: exploration of potential indicators
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3.1 Systematic review search results
A total of 1046 unique abstracts were screened to give 66 included studies (Figure 1). 
The references that are cited in this section appear in Appendix 6. Studies were 
conducted in the UK1-10, USA11-25, Denmark26, 27, Norway28, 29, Austria30, Germany31-36, 
Greece37, 38, Italy34, 39-41, Spain42, 43, New Zealand44, 45, France46-50, Canada25, 48, 51-54, 
Israel55, Sweden56, 57, Switzerland35, Australia58, 59, Ireland60, 61, Netherlands62, Estonia63 
and three multi-country studies covering more than ten European studies64-66. 
The 66 Included studies covered 40 rare diseases or categories of rare disease. 
The majority of these diseases were only investigated in one or two studies, with the 
exception of cystic fibrosis (13 studies), Fabry disease (4 studies) and Fragile X (3 
studies) as shown in Table 1.
3. How has the 
rare disease 
diagnostic 
odyssey been 
assessed?
Figure 1 PRISMA flow diagram showing screening and selection of studies
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Full text articles
assessed for eligibility
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Records excluded
(n = 878)
Full-text articles 
excluded
(n = 102) 
Studies included 
(n = 66)
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Table 1 Frequency of rare diseases investigated by included studies
Disease Number of studies
Cystic Fibrosis 13
Fabry Disease 4
Fragile X 3
Alpha1-antitrypsin deficiency, Bronchiectasis, Duchenne muscular dystrophy, Haemophilia, 
Infantile Spasms/West Syndrome, Niemann-Pick disease type C, Takayasu arteritis
2
Acquired Angioedema, Adult-onset Still’s disease, Amytrophic lateral sclerosis, Batten 
Disease/neuronal ceroid lipofuscinosis, Cerebrotendinous xanthomatosis, Cervical 
Dystonia, Chylomicron retention disease/Anderson’s disease, Clarkson’s disease/
Idiopathic systemic capillary leak syndrome, Complex regional pain syndrome, Congenital 
Dyserythropoietic Anemia Type I, Congenital Hypothyroidism, Dopa-responsive dystonia, 
Dystonia or hemifacial spasm, Erythromyalgia, Familial amyloid polyneuropathy, Gastric 
Cancer, GM2 gangliosidosis, Hereditary angio-oedema, Hirschsprung’s Disease, 
Homocysteinuria, Inborn errors of metabolism, Juvenile dermatomyositis, Long QT 
syndrome, Lymphangioleiomyomatosis, Marfan Syndrome, Myasthenia gravis, Myotonic 
dystrophy, Porphyria, Primary immunodeficiencies, Primary myoclonus-dystonia, 
Pyridoxine dependent seizures, Variant Creutzfeldt-Jakob Disease
1
3.2 Method of data collection
The most common data collection method was retrospective case record review, 
followed by data already held within disease-specific databases and information from 
patient/family by questionnaire or interview (Table 2). 
Sample sizes ranged from 827 to 27,69216, with a median of 98 patients. Studies that 
required clinicians to complete special questionnaires or perform direct consultations 
had smaller sample sizes, while those using disease-specific databases had the largest. 
Existing routine data were used in 26 studies while the rest collected new data. Not 
surprisingly the former studies included more patients (mean sample sizes 1667 and 
230 respectively). The majority of studies (n=43) collected data retrospectively.
Data collection method Number of studies Mean sample size
Retrospective case record review 34 187
Disease-specific database 15 2777
Patient/family: questionnaire 
or interview
11 211
Clinician: questionnaire 7 65
Specialist questionnaire 5 63
Surveillance unit 4 97
Facility database 3 1211
Generic database 2 1311
Table 2 Number of studies and mean sample size by data collection method
Studies using multiple data collection methods are recorded more than once.
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3.3 Representativeness of patient populations
There are several potential challenges to ensuring that data on people with rare 
diseases are representative of the entire population of such people: 
i. patients with mild symptoms may not present to a doctor 57, 63 and, conversely, 
those with severe symptoms may die before a diagnosis can be made52; 
ii. if diagnosis relies on clinician judgement (rather than an accurate diagnostic test), 
some patients may remain undiagnosed8; 
iii. if diagnosis depends on a diagnostic test that is not widely available, cases may 
be unrecognised;
iv. if inclusion of cases in a database depends on voluntary reporting by doctors 
rather than active case finding, recruitment is likely to be incomplete which may 
bias the information; 
v. diagnosis may later be revised after the benefit of a longer period of observation28, 56; 
vi. databases held by pharmaceutical companies may be biased towards those 
who are eligible for treatment; those with co-morbidities that contraindicate the 
treatment or who are unable to access the treatment may be under represented11; 
vii. given that patients can only be included once they are diagnosed, databases will 
be biased towards those whose time to diagnosis is shorter26;
viii. if diagnosis depends on a new test, its introduction will detect previously 
unrecognised cases that never contributed to the estimation of time to diagnosis. 
As a result, the time to diagnosis for patients with that condition may increase, 
suggesting a deterioration in the service rather than an improvement51; 
ix. where a sampling frame is limited to a particular specialty or department, patients 
managed primarily by other specialties may be missed. For example, patients 
with primary immune deficiency are normally managed by immunologists but 
some specific disease are managed in haematology or rheumatology36.
3.4 Definition of start and end of time to diagnosis
The most common definition to mark the beginning of time to diagnosis was that of 
symptom onset, used in 49 studies (Table 3). Many studies gave little or no information 
about how symptom onset was operationalised for data collection – those that did are 
shown in Appendix 7. Specific symptoms were either defined in advance, particularly 
studies collecting data from large databases32, 33, or were elicited through open 
questions to ascertain the start of symptoms or concerns. 
Definition of start of time to diagnosis Number of studies
Birth 14
Symptom onset 49
Presentation – primary care 9
Presentation – secondary care 3
Presentation – tertiary care 4
Not specified 1
Table 3 Frequency of choice of start of time to diagnosis
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Fourteen studies used the patient’s date of birth to mark the beginning of time to 
diagnosis for congenital or genetic conditions. A minority used the date of first 
presentation to primary care (or any health care worker) and a few used presentation 
to specialist care in order to focus specifically on health service delays to diagnosis.
Most (94%) studies used the date of definitive diagnosis to mark the end of time to 
diagnosis. One study specified that they considered the diagnostic odyssey to end 
only when that result had been communicated to the patient 34. 
Three studies used the date of probable or presumptive diagnosis: one on congenital 
hypothyroidism was conducted in 1978 when laboratory tests were new and symptomatic 
diagnosis was common53; one on variant Creutzfeldt-Jakob Disease where a definitive 
diagnosis is only possible post-mortem9; and one on inborn errors of metabolism 
defined a diagnosis once ‘clinical history, physical examination and initial laboratory 
investigations pointed to a condition and therapy and counselling were instituted’ 54. 
Of the four studies that used the commencement of disease-specific clinical management 
as a proxy for diagnosis, one of particular note used the date of referral to a specialist as 
a proxy for the diagnosis of complex regional pain syndrome55, making the assumption 
either that a referral would not occur unless a diagnosis had been made, or that the 
specialist clinic would be guaranteed to make the ‘correct’ diagnosis immediately. 
Notable limitations for defining the start and end points include: 
i. the challenge of balancing the specificity of symptoms defined as heralding the 
onset of the disease and the danger of excluding or under-representing non-
specific or non-classical symptoms; 
ii. ascertaining symptom onset is likely to require patient-reported data which may be 
subject to recall bias if asked at or after the time of diagnosis50; 
iii. relying on health care professionals reporting may misrepresent patients’ views66 
and precludes the ability to prompt for more subtle, earlier signs of disease 23; 
iv. using presentation to a particular level of care as a starting point for time to 
diagnosis excludes those who have never entered that level of care, for example 
those using centres in a different geographical area45, milder cases or those who 
were felt unsuitable or did not want specialist care53; 
v. studies using start of treatment as a proxy for date of diagnosis make the 
assumption that treatment starts soon after a diagnosis is made25.
3.5 Types of analysis of time to diagnosis
The majority of studies (n=42) reported means or medians of time to diagnosis. One 
study noted a bimodal distribution of time to diagnosis: patients were either diagnosed 
quickly on presentation or experienced a prolonged delay (or were never diagnosed)54. 
Therefore parametric tests or summarising time to diagnosis using means or medians 
may fail to represent the actual odyssey that people experience. 
Definition of end of time to diagnosis Number of studies
Definitive diagnosis 62
Probable diagnosis 3
Treatment/disease specific management started 4
Table 4 Frequency of choice of end of time to diagnosis
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4. What can 
be learnt from 
other clinical 
areas? 
A search revealed potentially helpful attempts to assess the diagnostic odyssey in two 
other clinical areas – cancer and diabetes. Four different approaches have been used 
that might be considered for rare diseases. 
4.1 One-off national service evaluation
Concern about delays in cancer diagnosis led to the establishment of a service evaluation, 
the National Audit of Cancer Diagnosis in Primary Care [7]. Conducted in 2009/10 in 1170 
general practices in England, data on 18,879 patients who had a confirmed malignancy 
were collected from clinical records and hospital correspondence. Three intervals 
were identified within the diagnostic pathway: patient interval, that is time between the 
first symptom and the first consultation; primary care interval, the time between first 
presentation and date of referral (the number of consultations for relevant symptoms 
that they had with a GP before referral was also collected) and referral interval, 
defined as the time between referral and first specialist consultation.
4.2 General practice research databases
Another approach in cancer care involved use of the General Practice Research 
Database (GPRD) which includes data on about 10% of the population. Patient data 
were extracted to compare the length of the whole diagnostic interval (time between 
first presentation with symptoms attributable to cancer and cancer diagnosis) in two 
cohorts of patients, one diagnosed in 2001-2002 and the other in 2007-2008 to see if 
the time to diagnosis changed after the adoption of the 2005 NICE Referral Guidance 
for Suspected Cancer [9, 10]. This work suggests that data included in GPRD (now 
incorporated in the Clinical Practice Research Datalink, CPRD) may be accurate and 
detailed enough to attribute recorded symptoms to later diagnoses, using a set of 
putative symptoms derived from the literature or diagnostic guidelines.
4.3 Primary care information systems
The National Adult Diabetes Audit, the largest annual clinical audit in the world, 
collected primary care data from 2.47 million patients in 2011/12 [11]. Although the 
diagnostic pathway is not a focus of the audit, it illustrates how primary care data 
are potentially an effective option for studying this topic. Until concerns were raised 
about care.data, data were extracted by local primary care staff. The data required 
was specified by the Health & Social Care Information Centre (HSCIC) and extraction 
processes were produced to be run on the different information systems that general 
practices use to store health records [12]. In time it is hoped to extract data using the 
General Practice Extraction Service (GPES) which will offer greater flexibility and not 
require any work for local primary care staff [13]. 
4.4 National disease registries
The National Cancer Research Service collects data from the cancer registries in 
England. Data from the eight English registries are combined with similar data from 
the rest of the UK by the National Cancer Registration Service. It includes data on 
the date of referral from primary care and date of diagnosis so provides a model for 
determining the specialist care interval. 
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The definition of key time points in the Aarhus statement [6] was adapted to inform 
the proposed conceptual framework. A number of theoretical choices were made, 
influenced by the literature review and of the opinions of the experts interviewed.
The framework recognises four time points (Figure 2):
 • date of onset of symptom/s: defined as the first time the patient /parent notices 
what will later be classified as a symptom of the disease;
 • date of presentation to primary care: time at which it would be feasible for a 
clinician to start investigating or referring to specialist care;
 • date of referral to specialist care: time at which responsibility for the diagnosis 
shifts to specialist (secondary or tertiary) care. When there is direct presentation to 
emergency or to secondary care, such an interval would be zero; 
 • date of diagnosis: time when the final diagnosis is given to the patient. 
The four time points allow three intervals to be calculated:
 • patient interval: between the time of onset of symptoms and the presentation to 
primary care; includes the waiting time for an appointment;
 • primary care interval: between the first presentation to primary care and referral to 
specialist (usually secondary) care;
 • specialist care interval: time between the first referral and diagnosis; includes 
waiting time for an appointment. May involve further referrals from ‘general 
specialist’ such as general paediatrician to specialist in tertiary care.
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Figure 2 Conceptual framework
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Five categories of databases were identified that offer opportunities of providing 
information about rare diseases diagnostic odysseys: generic hospital databases; primary 
care databases; rare diseases databases; specialist department databases; and the 
recently established National Congenital Anomaly & Rare Disease Registration Service.
6.1 Generic hospital databases
Hospital Episode Statistics (HES) collects data about all episodes of hospital care being 
provided by NHS hospitals in England (with similar systems in the other parts of the UK) 
[14]. In theory, once a person had been diagnosed with a rare disease, their previous 
outpatient consultations and inpatient episodes could be identified. Thus, a picture of 
their odyssey from date of referral to specialist care could be constructed. In addition, 
patients could be linked to other databases (see below) to complete the odyssey.
In practice, shortcomings in data completeness, accuracy of the diagnostic data, 
and difficulties in linkage (partly due to failure to always use patients’ NHS numbers) 
severely limit the capability of HES. As a result, the information on rare diseases 
odysseys would be incomplete and may be misleading if systematic biases exist in 
the data collection (eg more complete data for those patients with shorter odysseys). 
In practice, no examples of using HES to inform the odyssey were found.
6.2 Primary care information systems
Primary care is theoretically the best setting to collect data about the diagnostic 
odyssey in rare diseases, given that virtually all information about the patient’s clinical 
pathway is supposed to be either generated by primary care or transmitted to it by 
other care providers. GP information systems should contain data which would be 
accurate enough to measure the diagnostic odyssey of rare diseases.
General practices use one of several information systems to manage their clinical 
records. There are four main providers: INPS, EMIS, Microtest and TPP. Until late 
2012 a fifth provider existed (CSC, iSoft system) but has since been withdrawn 
from the market [15]. Data from these systems are increasingly being used to 
create aggregated databases either for research purposes or for service functions 
(management, reimbursement, clinical audit). 
Research 
The three main databases constructed for research from GP systems are the CPRD, 
THIN, and QResearch.
(i) Clinical Practice Research Datalink (CPRD)
This routinely collects data from general practices in the UK using INPS Vision 
software from self-selected practices that have volunteered to participate. It is funded 
by the National Institute of Health Research (NIHR) and the Medicines and Healthcare 
products Regulatory Agency (MHRA) and covers about 10% of the population [4, 16]. 
In March 2011 it contained records from over 12 million patients and by December 
2013, there were over 13 million patients, of which approximately 5.5 million were 
active. The CPRD aims to link data from what was previously known as the General 
Practice Research Database (GPRD) with HES and other patient databases. Such 
linkage is reported to be currently available for about 60% of the participating 
practices. Many research studies have used GPRD data (either before or after its 
incorporation in the CPRD): 1159 publications in 1988-2013 [8].
6. What can 
existing 
databases 
contribute? 
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One example of a study of a rare disease was the determination of the prevalence 
of Huntington disease in UK [17]. Another example of use of these data for a rare 
disease is a study being carried out at IMS Health, in collaboration with Novartis 
Pharmaceuticals, where the clinical pathway of patients with tuberous sclerosis 
is being constructed from GP data linked to HES data [18]. Time to diagnosis in 
these patients is not a specific focus but data that has been extracted, cleaned and 
consolidated would allow this kind of measurement to be made.
(ii) The Health Innovation Network (THIN) 
Data collected by general practices using the INPS Vision software is also available 
through this database. It was developed from GPRD but, since 2002, it has been 
independent and run commercially by CSD Medical Research UK (formerly known 
as EPIC). Many general practices using INPS Vision provide data to both databases. 
THIN covers 587 practices and contains data on 12.3 million patients, 3.6 million of 
which are active. It is commonly used in research: 477 research papers published in 
2004-2014 relied on data extracted from THIN [19].
(iii) QResearch
This is a database that collects data from general practices using the EMIS 
information system [20]. It is jointly owned by the University of Nottingham and EMIS. 
It currently gathers data from 950 general practices (about 12% of all practices), 
including health records from over 13 million patients. The number of practices 
participating has increased significantly since 2006. Around 200 research papers 
have been reported on the QResearch website since 1998. Data from QResearch has 
been extensively used to derive risk prediction algorithms for a number of conditions.
Two issues were identified as specifically associated with the use of data from 
these research databases. First, there is concern about the representativeness of 
the data. Although this has been thoroughly assessed and is generally considered 
to be acceptable [21], it has not been established in the case of rare diseases. 
Because of their rarity, a partial coverage of English patient records together with 
the low prevalence of cases may substantially affect the statistical power and the 
generalisability of the measurements made. Second, there are concerns about the 
truncation of data. Since these databases are restricted to a small sample of general 
practices, patients moving in and out of practices will truncate the data and provide 
incomplete information. The impact of this as regards measuring a diagnostic odyssey 
needs to be assessed.
Service use
To overcome concerns about the representativeness of data from self-selected 
practices participating in research databases, increasingly there are opportunities 
to extract data from all practices. There are two principal approaches to obtaining 
patient-level data: local extraction and central extraction.
(i) Local extraction
This requires the cooperation and involvement of staff in each and every general 
practice who have to interrogate their local information system. This is the approach 
used to obtain data centrally for the Quality & Outcomes Framework for which 
practices have a strong financial incentive to participate. There are two recent 
examples of use of this approach in cancer and adult diabetes.
The NACDPC recruited general practices and asked them to extract data on cancer 
patients from their information system. It had to be reported in a standard way by 
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entering the data into a spreadsheet. This approach gave good results in terms 
of participation and validity, where representativeness of data was found to be 
satisfactory when compared with cancer registry data.
The National Adult Diabetes Audit used a strategy designed centrally but with an 
application for each of the brands of software in use locally. In other words, the terms 
used to identify patients with diabetes and those used to identify the data that were 
being requested were translated into the different languages that local systems use. 
Each participating practice ran a number of instructions prepared by the NDA for their 
system and obtained the data that needed to be returned. Most (88%) of general 
practices in England participated in 2011-2012 and the quality of data collected was 
reported to be excellent [22]. The method depended on local staff downloading the 
extraction software, running it and transmitting the output to the Health & Social Care 
Information Centre (HSCIC).
(ii) Central extraction 
To overcome additional work for local general practice staff and to ensure 100% 
coverage, the General Practice Extraction Service (GPES) was conceived. It is to be 
hosted by HSCIC and is intended to provide data from all the main general practice 
information systems. Once up and running, the GPES will provide access to a much 
larger proportion of English patients’ primary care records than existing databases. 
Currently technical challenges and political concerns about patient confidentiality are 
impeding progress to establish the GPES. Thus the level of accuracy of the data it 
would provide or its consistency is not known. No published use of this extraction 
system has been identified from web and database searches. Although extremely 
promising for the future, the GPES cannot yet be considered as a viable option to 
measure the diagnostic odyssey in rare diseases.
Three issues were identified as specifically associated with the use of data from 
these service databases. First, there are transcription issues. Currently, information 
generated in secondary care, such as a diagnosis made by a specialist, needs to be 
manually transcribed into primary care records. This may or may not happen and, 
if it does, there is a danger of errors being introduced. Letters reporting a diagnosis 
may simply be attached as document files to the patient record, or written in an open 
text comment, but not properly coded as such. This means that querying a primary 
care database for patients with a specific diagnosis may miss cases and that a more 
complicated and possibly iterative process could be needed. 
Second, there are coding issues. The Read Codes used in primary care clinical 
information systems is unlikely to be specific enough to allow the correct identification 
of some (many) rare diseases. In addition, the lack of a code for a rare disease 
will lead to inconsistent coding, with the same condition being coded differently in 
different patients.
Finally, there are limitations in the reporting of symptoms before a diagnosis is made. 
The probability that the first symptoms of a rare disease are timely and accurately 
reported at presentation depends on their severity, the specificity of available codes 
and on clinician judgement. This means that the same symptoms may or may not be 
reported by different clinicians for different patients. This risk is likely to be higher with 
more unspecific and less severe symptoms.
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6.3 Rare disease databases
Orphanet identifies 74 unique rare disease databases in England. However, 26 did not 
meet the inclusion criteria of this review and were excluded: 12 were regional rather 
than national in coverage (mostly congenital anomaly registers which were included 
as part of the British Isles Network of Congenital Anomaly Registers); nine were 
conditions obvious at birth or already targeted by screening; and five were cancer or 
acute diseases.
Of the 48 databases meeting the inclusion criteria, 32 had an active, functioning 
website (Figure 3). Of those, 22 provided some information on the data variables 
collected including 12 that provided details. The details were either contained in a 
data dictionary or in a protocol for the database. As regards the diagnostic odyssey, 
five collected both the time of onset of symptoms and the time of diagnosis. It is 
possible that a larger number of databases collect such data but either the data 
dictionary was not available online, or access was restricted to those registered or 
contributing data.
In those databases that collect data about time of onset of symptoms and time of 
diagnosis, the definitions used to identify such events were generally vague. Thus the 
validity of these data should be appraised before being accepted and used.
Figure 3 Summary of databases collecting data about rare diseases in England
Included databases = 48
Databases with a working website = 32
Websites providing information about collection data = 22
Websites providing detailed list of data = 12
Websites with a 
private area
= 10
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= 6
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AND 
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6.4 Specialist department databases
Some specialist departments (such as clinical genetics laboratories or centres for 
investigating and treating rare metabolic conditions) have created their own databases. 
While some may include information on the diagnostic odyssey, they are inevitably 
limited in scope to the experiences of a single specialist centre. Despite this limitation, 
such specialist databases could assist in identifying patients with a rare disease. 
The National Pulmonary Hypertension Audit, managed by HSCIC, is an example 
of how specialist department databases can be used to collect patient-level 
data on a rare condition [23]. All eight centres designated for the care of patients 
with pulmonary hypertension in the UK participate, collecting data on patient 
demographics, diagnosis, clinical management and survival. The audit does not 
collect data on time to diagnosis but its functioning mechanism could be replicated 
for other conditions, where a limited set of centres for specialist care exists.
Although a disease that is diagnosed by means of a genetic test is not synonymous 
with it being a rare disease, a large number of the latter involve genetic testing as part 
of their diagnostic odyssey. Databases run by different genetic laboratories are unlikely 
to record information about onset of symptoms but as they always include a patient’s 
NHS number, linkage to other databases could prove fruitful. In addition, specialist 
department data will have high validity and accurate coding. There are 32 laboratories 
in the UK Genetic Testing Network so establishing a national data collection system 
appears feasible, although a detailed assessment would need to be carried out. 
6.5 National Congenital Anomaly & Rare Disease Registration 
Service (NCARDRS)
Public Health England is currently creating a single comprehensive national congenital 
anomaly and rare disease registration service. Their vision is influenced by their 
experience of creating and managing the National Cancer Registration Service 
(NCRS). As the NCARDRS is currently at an early stage of development it is not yet 
clear what its structure and contents will be. The aim is that all rare diseases identified 
in the internationally recognised Orphanet rare disease classification system will be 
included. The service will provide data for patients, their families, clinicians, public 
health and research to improve monitoring of the frequency, nature, cause and 
outcomes of congenital anomalies and rare diseases [24].
The Registration Service will encompass the existing British Isles Network of 
Congenital Anomaly Registers (BINOCAR), which covers about half the population, 
with plans to extend it to the whole country by the end of 2015. BINOCAR currently 
collects data on 89 conditions, 60 of which are listed as rare diseases. Given that the 
majority of these conditions are diagnosed prenatally or immediately after birth, this 
initiative will not meet concerns about prolonged diagnostic odysseys. Nonetheless 
the wider vision of the NCARDRS, which plans to use rare diseases databases 
and seeks to identify affected people from other sources, may have something to 
contribute to measuring diagnostic odysseys.
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There are three existing sources of data that could provide data on the diagnostic 
odyssey – general practice information systems, GP research databases, specialist 
department databases – and two potential sources that either are being planned 
– NCARDRS – or could be established – patient/parent surveys. We consider the 
strengths and limitations of each as well as the developmental opportunities that exist 
to enhance them.
7.1 Primary care information systems
Local general practice information systems contain clinical data on all registered 
members of the population. Diagnoses are identified by Read codes.
Strengths
 • general practice clinical records contain detailed data about all episodes of primary 
and secondary care received by each patient which could identify the key points in 
the diagnostic odyssey;
 • systems cover all patients registered in the UK; people with rare diseases are likely 
to be registered;
 • may be possible to identify first presentation of what later turn out to be relevant 
symptoms/signs. 
Limitations
 • the Read codes, by which symptoms and diagnoses are coded, may not be 
detailed enough to identify all rare diseases;
 • the time of onset of symptoms may not have been recorded;
 • data extraction awaits the successful implementation of GPES;
 • practices would have to be individually enrolled, though could be part of overall 
agreement for all national clinical audits;
 • information governance issues (care.data) need to be addressed;
 • key items of data may not be in the GP’s electronic record but in letters and 
documents from specialist care, accessible only by free text scanning of attached 
documents. 
Development opportunities
 • lack of detail in Read codes could be addressed if diagnoses were validated 
from other sources (by linkage to HES, rare disease databases, and specialist 
department databases); or national monitoring could be restricted to a ‘basket’ of 
rare diseases for which Read coding is adequate;
 • time of onset of symptoms could be estimated by GPs but compliance by GPs 
and accuracy (hindsight bias) uncertain;
 • GP participation rates are likely to increase if a financial Incentive (as with the QOF) 
is deployed;
 • as and when GP Extraction Service becomes available, there will be no extra 
workload on practice staff (though the level of participation by practices may be 
less than 100%); 
 • estimates of cost could be obtained from a review of the costs associated with 
NDA and with NACDPC. Similarly, lessons could be learnt about information 
governance issues.
7. Options for 
monitoring the 
rare disease 
odyssey 
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7.2 Primary care research databases
These databases (CPRD, QResearch and THIN) provide higher quality data than GP 
data information systems in general but are restricted to samples of self-selected 
practices that may not be representative. 
 
Strengths
 • data have been checked, cleaned and shown to be meet certain quality standards;
 • strong cooperation with the participating practices would facilitate any additional 
data requirements.
Limitations
 • the Read codes, by which symptoms and diagnoses are coded, may not be 
detailed enough to identify all rare diseases;
 • the time of onset of symptoms may not have been recorded by those entering data;
 • data truncation may affect the validity of measured time to diagnosis;
 • each database covers a limited proportion of UK population: CPRD (the largest) has 
about 5.5 million patients, about 10% of the population. This will limit the statistical power 
of diagnostic odyssey measurements, particularly for diseases of very low prevalence.
Development opportunities
 • lack of detail in Read codes could be addressed if diagnoses were validated from 
other sources (by existing linkage to HES or new linkages to rare disease databases 
and specialist department databases); or national monitoring could be restricted to a 
‘basket’ of rare diseases for which Read coding is adequate;
 • time of onset of symptoms could be estimated by GPs though accuracy (hindsight 
bias) uncertain;
 • combining data from the three major databases (CPRD, THIN and Qresearch) would 
increase statistical power.
7.3 Rare disease databases
A small number of rare diseases have a specific national database (register) that 
includes patient level data.
Strengths
 • data have been checked, cleaned and shown to be meet certain quality standards.
 • use of multiple sources to identify all cases should ensure high sensitivity and 
specificity for cases included;
 • database custodians are likely to be well motivated to make data available for 
monitoring diagnostic odyssey;
 • likely to have high credibility with patients/parents and clinicians;
 • some databases have strong patient/parent involvement and sense of ownership.
Limitations
 • only five such databases that include data on time of onset of symptoms/signs and 
time of diagnosis have been identified, but more may exist;
 • the representativeness and completeness (sensitivity) of cases included is unknown 
but likely to vary between databases.
Development opportunities
 • many other existing rare disease databases may be able to expand their datasets to 
include information on the odyssey at minimal extra burden or cost.
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7.4 Specialist department databases
Many specialist facilities (hospital departments, clinical genetic laboratories) maintain 
their own databases, holding administrative and clinical information at patient-level. 
As they directly support the clinical management of patients, the data are detailed, 
complete and up-to-date. 
Strengths
 • high volume of patients with a range of rare diseases;
 • appropriate for the rarest conditions and conditions managed in one or a small 
number of facilities;
 • quality and completeness of data likely to be high; 
 • likely to be amenable to addition of additional data variables on odyssey; 
 • likely to have high credibility with patients/parents and clinicians;
 • database custodians are likely to be well motivated to make data available for 
monitoring diagnostic odyssey.
Limitations
 • not so useful for conditions that are managed at different levels of care, or in 
multiple facilities in a given catchment area; 
 • lack of standardisation of data collected between specialist facilities could limit 
opportunities for aggregating data to gain national information;
 • limited in scope by geography (unless a national centre) and disease type – those 
not treated or tested for in specialised facilities will not be included;
 • unlikely to collect data on early phases of diagnostic odyssey;
 • lack of clear catchment population may lead to some patients being excluded. This 
may underestimate length of odyssey as those missed likely to experience longer 
journey;
 • datasets collected may have altered over time limiting longitudinal monitoring;
 • facilities that maintain the best databases may also be those that minimise the 
length of the odyssey, this biasing the results. 
Development opportunities
 • specialist facility databases which currently do not include data on the odyssey 
could add variables on time to diagnosis; 
 • the UK Genetic Testing Network provides an opportunity to create national 
information through sharing data from specialist facilities. 
7.5 Patient/parent survey
Rather than relying on clinical records, an alternative approach would be to collect 
information from patients/parents using survey methods. 
Strengths
 • allows collection of data on when the first concerns occurred, which may be 
missing from clinical records; 
 • good method for identifying time at which the diagnosis was communicated to the 
patient/parent, which may be an important component of the odyssey;
 • captures not only the patient/parents’ objective view of the length of the odyssey 
but also their subjective judgement as to the acceptability of it; 
 • could also collect information on the quality of the odyssey (eg emotional impact of 
‘looping’ through different specialties and hospitals with unnecessary repeat tests, 
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whether or not their condition is taken seriously, number of wrong diagnoses that 
preceded the correct one); 
 • patients/parents likely to be highly motivated to participate so high response rates; 
 • likely to have additional benefits by empowering patients/parents and providing 
feedback of concerns to stimulate improvements in services. 
Limitations
 • expensive and resource intensive to collect new data routinely; 
 • patients/parents judgement of attribution of relevant symptoms/signs may be 
inaccurate; 
 • subject to recall bias as patients/parents can only be asked about the onset of 
symptoms/first presentation after the final diagnosis is made, in some cases 
several decades later.
Development opportunities
 • lessons could be learnt from those rare disease databases that already incorporate 
patient/parent surveys. 
7.6 National Congenital Anomaly & Rare Disease Registration 
Service (NCARDRS)
The NCARDRS is planning to start incorporating rare diseases during 2015. When 
it is fully operational it could monitor the diagnostic odyssey. It’s difficult to assess 
its strengths and limitations until more detail becomes available so what follows is 
somewhat speculative.
Strengths
 • it would provide a comprehensive, single national database covering the whole of 
England;
 • data will have been checked, cleaned and shown to be meet certain quality 
standards;
 • use of multiple sources to identify all cases should ensure high sensitivity and 
specificity for cases included;
 • likely to have high credibility with patients/parents and clinicians;
 • high volume of patients with a range of rare diseases;
 • NCARDRS are amenable to addition of additional data variables on odyssey; 
 • database custodians are likely to be well motivated to make data available for 
monitoring diagnostic odyssey.
Limitations
 • it is still at an initial stage and is designed to be implemented in stages. So the 
ability to measure diagnostic odysseys may be some way off;
 • current plans do not include routine data from primary care which would be 
necessary to measure the diagnostic odyssey.
Development opportunities
 • being at an initial stage of development, it offers an opportunity to include the 
measurement of diagnostic odyssey within its scope.
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7.7 Summary of options
The options have been assessed against the following nine criteria:
 • range of rare diseases included;
 • information on diagnostic odyssey: extent to which data are included;
 • representativeness of cases included: extent of selection bias; 
 • accuracy of case recruitment: sensitivity (no false negatives) and specificity (no 
false positives); 
 • data completeness: extent to which missing data might bias findings; 
 • validity of data: on diagnostic odyssey;
 • credibility: how meaningful the data are to patient/parents and clinicians; 
 • timeliness: how up-to-date the data are; 
 • burden and cost of additional data collection: additional time and expense to 
provide data on diagnostic odyssey. 
For each criterion, the extent to which each option does or could satisfactorily meet 
the requirement has been judged as: 
Red = considerable limitation
Orange = some limitation
Green = no existing limitation
Given uncertainty as to what the capabilities of the National Congenital Anomaly & 
Rare Disease Registration Service will be, it was not possible to assess it.
Figure 4 Assessment criteria for six potential data sources
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8.1 Key considerations in formulating a solution
No single data collection approach can accurately and cost-effectively collect routine 
measurements of the diagnostic odyssey for all 5000-8000 rare diseases across the 
whole of the UK. The heterogeneity of diseases as regards their symptoms, signs, 
pathology, and natural history means that patients’ experiences and diagnostic 
pathways vary. This, combined with the rarity of each disease, means that we 
recommend that monitoring of the odyssey should be retrospective in design 
and focus on a ‘basket’ of tracer diseases. 
i. Retrospective approach
Given the low incidence of rare diseases, assessment of the diagnostic odyssey 
will inevitably need to start with the endpoint (when the diagnosis is eventually 
made) and then retrospectively look back at the events and timings of steps 
along the journey. This means that the completeness and accuracy of the 
odyssey will depend on the data collected at the time (eg date of referral from 
primary care) or on the recall of such events by patients/parents or clinicians. 
ii. Tracer conditions
It is not feasible to assess the diagnostic odyssey for all rare diseases. The selection 
of ‘tracer’ conditions needs to maximise the generalisability of the results to the 
wide range of rare diseases that exist. To achieve this, the following criteria should 
be observed in determining suitable rare diseases for consideration:
 • relevance: evidence (which may well be anecdotal) that prolonged odysseys 
exist and that it has an adverse impact on patients/parents;
 • disease prevalence: sufficient to provide an acceptable statistical power to 
detect the impact of policy/practice interventions;
 • diagnostic specificity: sufficient to be able to isolate condition by codes used 
in routine databases;
 • existence of tell-tale presenting symptoms and signs: to enable a date to be 
determined at which a health professional could reasonably be expected to 
actively consider a diagnosis of a rare disease.
In selecting tracer conditions from those that meet these criteria, it would be 
advisable to include a range that reflected not only the variety of diagnostic categories 
(eg musculoskeletal, metabolic, developmental etc) but also that involved a range of 
diagnostic specialties (eg clinical genetics, imaging, biochemistry etc). 
Although there is no suitable single source of data available, a combination of 
existing sources, with some enhancements, could produce a feasible way forward. 
We recommend the use primary care data as the foundation and to build on 
that through more specialist data sources such as rare disease databases and 
specialist department databases. In addition, patient/parent surveys could 
enhance knowledge and understanding of the diagnostic odyssey still further. 
Details of such an approach are outlined below.
8. 
Recommendations 
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Patient interval Primary care interval Specialist care interval
8.2 Primary care databases
Ideally, information systems in all general practices would be used so that everyone 
with a diagnosis of a rare disease could be identified. However, currently that is not 
feasible due to technical limitations with extracting data remotely (without burdening 
general practice staff with additional work), and political concerns about patient 
confidentiality that are restricting access to and the use of such data. Until these 
issues are resolved, alternative approaches must be used. Whilst not perfect, they 
may be fit-for-purpose if the data are handled cautiously.
We recommend the use of primary care research databases. The feasibility 
of identifying patients has already been demonstrated for tuberous sclerosis and 
Huntington’s disease, and the cost is relatively low (Figure 5). The principal limitations are:
 • the range of diseases to be included in the basket would be limited by the 
specificity and sensitivity of Read codes;
 • the restricted coverage of the UK population to self-selected general practices may 
bias the findings (though this could be minimised by combining data from several 
research databases);
 • the lack of data on the patient interval would preclude measuring the effects of 
interventions aimed at reducing it. 
As and when it becomes possible to extract data from all general practices (using 
the General Practice Extraction Service), the sample sizes will be much enlarged 
and selection bias will be minimal (Figure 6). There will still be the issue of the lack of 
specificity and sensitivity of Read codes for some rare diseases. The work to design 
the queries for data extraction will be able to capitalise on experience from working 
with the primary care research databases.
Figure 5 Diagnostic intervals for rare diseases covered by primary care research databases and 
coverage of population
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Figure 6 Diagnostic intervals for rare diseases covered by GP information systems and coverage of 
population
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8.3 Supplementary sources
The foundation provided by primary care data can be enhanced and validated by 
the addition of data from three other sources: rare diseases databases; specialist 
department databases; and patient/parent surveys.
Rare diseases databases
Although relevant for only a limited number of diseases, we recommend the use of 
rare diseases databases to enhance the data from primary care. Using patient 
identifiers, data from rare diseases databases could be linked to primary care research 
databases at the individual level (subject to meeting confidentiality requirements). This 
would help inform the primary care and specialist care intervals in the diagnostic odyssey. 
Meanwhile, the custodians of rare diseases databases should be encouraged to 
include data that allows all three intervals in the odyssey to be determined.
Specialist department databases 
In a similar way, we recommend that patients identified in primary care research 
databases be sought in databases run by specialist departments. The strengths 
of these databases are the high number of patients with rare diseases included. We 
recommend including:
 • genetic sequencing centres: a large and increasing number of rare diseases are 
diagnosed using genetic tests carried out by a small number of regional or national 
reference laboratories. Utilising their electronic records, supplemented by a small 
number of specific questions concerning time to diagnosis on test request forms, 
gives access to a large number of patients with rare diseases;
 • quaternary care centres specialising in rare diseases: their patients are likely to 
be those with a relatively long diagnostic odyssey. Although not generalizable to 
all patients with a rare disease, the most severely affected patients are those for 
whom it is arguably most important to improve time to diagnosis. 
Patient/parent survey
The principal gap in the information available from routine databases is data on the 
time of patients’/parents’ initial concern that there might be a problem (the start of 
the patient interval). We recommend the use of a patient/parent survey to help 
establish the patient interval. 
General practice research databases can’t be used to identify individual patients 
so it will not be possible to try and generate linked data. Instead, patients would 
need to be recruited through patient associations, rare diseases databases or 
specialist department databases. As data from different sources would be based on 
different patients, the assumption would have to be made that both sources were 
representative of the odysseys of all patients (Figure 7).
Figure 7 Diagnostic intervals for rare diseases covered by primary care research databases and 
survey, and coverage of population
Coverage of 
population with 
rare diseases Primary care research databases
10%
0%
Patient/parent survey
Patient interval Primary care interval Specialist care interval
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As and when primary care information systems can be utilised, patients/parents could 
be invited to participate in a survey by their GP, avoiding any information governance 
obstacles. Responses could then be linked to the routine databases at the individual 
level (ie data from both sources would relate to the same patients) (Figure 8). The survey 
need not be limited to the patient interval but could seek to validate the clinical records 
of the other two intervals. In addition the survey could obtain information on the ways 
the odyssey had affected patients’/parents’ quality of life, not just quantifying the length.
There would be additional work for participating practices but the low prevalence 
of patients with rare diseases would mean it was slight. Given the importance of 
the odyssey for most of those surveyed, a high response rate would be expected. 
However, given the large number of general practices (over 8000 in England), the 
work involved in managing a survey would be considerable, as would be the cost. 
8.4 The way forward
We recommend that these proposals be subject to widespread consultation 
among all those with an interest in and expert knowledge of the clinical, diagnostic 
and management aspects of the conditions and among those with expert knowledge 
of the relevant information systems. Whatever course of action is subsequently 
decided upon will need to be rigorously tested before widespread implementation.
We recommend that the feasibility of any proposals are tested in pilot studies 
of two or three rare diseases. This will enable a number of suppositions to be 
tested including: 
 • the ability to identify the diseases in the general practice research databases;
 • the feasibility of using more than one GP research database and whether there is 
sufficient added value to justify such a strategy;
 • the amount of information on the diagnostic odyssey that can be obtained from the 
GP research database/s;
 • the cost and benefit of supplementing such data with that obtained from rare 
diseases databases;
 • the cost and benefit of supplementing such data with that obtained from specialist 
department databases;
 • the feasibility and response rates of patient/parent surveys;
 • the feasibility of rare diseases databases and specialist department databases 
extending their datasets to include information on the odyssey.
Finally, whatever policy is adopted, it will need to be reviewed in the light of two 
promising prospects. Both the General Practice Extraction Service and the National 
Congenital Anomaly & Rare Disease Registration Service may provide better options 
for monitoring the diagnostic odyssey than the short-term solutions being proposed.
Figure 8 Diagnostic intervals for rare diseases covered by GP information systems and survey, and 
coverage of population
Coverage of 
population with 
rare diseases
10%
0%
   Patient/parent survey GP information system
Patient interval Primary care interval Specialist care interval
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Appendix 1 
Systematic 
review protocol 
and search 
strategies
Protocol registered 
at PROSPERO, 
registration number  
CRD42014013877
Research aim
To identify and synthesise existing quantitative research into the diagnostic odyssey of 
long-term, non-communicable rare diseases in OECD countries, with a primary focus 
on how studies have defined, collected and analysed time to diagnosis. 
A secondary aim of the review is to identify and extract data on what is known about 
the length and determinants of time to diagnosis. However, this will not be the primary 
focus of the synthesis and findings will be presented in the synthesis only where they 
aid interpretation of the usefulness of different research methods used. Data extracted 
on study findings will, however, be presented in results tables to allow their use by 
interested academics or clinicians. 
Review Methods
Inclusion and Exclusion Criteria
Rare diseases will be defined as any disease identified as a rare disease by 
www.orpha.net, www.eurordis.org or any condition that meets the criteria for a rare 
disease set out in the UK Strategy for Rare Diseases, namely ‘a life-threatening or 
chronically debilitating disease that affects 5 people or fewer in 10,000’.1
 
The aim of this review is to investigate methods for assessing diagnostic odysseys 
in patients with rare diseases that are often inherited or congenital, and may go 
undiagnosed for months or years. The causes and consequences of such diagnostic 
delays are sufficiently different from delays measured in minutes or hours in 
diagnosing acute conditions such as meningococcal meningitis (classified as a rare 
disease by orpha.net) to warrant separate consideration. The scope of the review will 
therefore be further limited to long term conditions of a non-infectious origin.
‘Diagnostic odyssey’ will be defined as: a time to definitive diagnosis longer that what 
the natural history of the disease and available technologies would allow, and whose 
delay may affect the health or emotional wellbeing of the patient or their family, their 
clinical management including secondary prevention and symptomatic treatment, 
or their access to social support services. The review will only include studies that 
measure time to diagnosis of a rare disease from an explicitly defined starting point in 
the disease pathway to a defined diagnosis date. 
The review will not be limited by language, place of publication or publication date. 
Foreign language texts will be translated by a member of the research team or 
colleague fluent in that language. All quantitative study designs will be considered, 
including descriptive designs, except case studies of one or a small number of 
patients which will be excluded as not sufficiently informative. However, given that in 
some ultra-rare diseases an entire country may only have a small number of cases 
of a particular disease, case series of the entire case population of a facility, region or 
country over a specified time period will be included in the review. 
In summary, studies will be included if they:
1. Were conducted in a World Bank defined OECD country
2. Measure, evaluate or seek to understand time to diagnosis, defined as length of 
time from onset of disease, onset of symptoms or presentation to any level of the 
health services until the correct diagnosis is made. 
1 Department of Health. The UK 
Strategy for Rare Diseases. London, 
UK; 2013. 
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Included: only age at diagnosis measured, where it was used by study authors 
as a marker of time to diagnosis in a congenital condition
Excluded: only age at diagnosis measured, where used by study authors as a 
marker of disease onset. 
3. Investigate one or more non-communicable, chronic rare diseases.
Excluded: time to diagnosis of a complication resulting from an underlying 
disorder, whether rare or not; rare subtypes of a common disease
4. Report explicitly defined quantitative measures of time to diagnosis in a population 
of patients with a rare disease. 
Excluded: studies that do not explicitly define the start or end points of the time 
to diagnosis measure 
Excluded: case study designs unless representing a complete case population 
of a facility, region or country over a specified time period  
Search Strategy
Medline, Embase and PsychINFO will be searched using search strategies based on 
the following broad logic:
[rare disease] AND [diagnostic odyssey] AND [quantitative study design] AND 
[OECD country]
Full search strategies for each database are given below. Of note, synonyms of rare 
diseases alone were felt unlikely to retrieve all relevant articles, while it was not feasible 
to include specific terms for the several thousand rare diseases currently known. As a 
pragmatic compromise, eight rare diseases (namely Crohn’s disease, cystic fibrosis, 
Duchenne’s muscular dystrophy, Ehlers-Danlos Syndrom, Marfan syndrome, Prader-
Willi Syndrome, Tuberous Sclerosis and Fragile X syndrome) that were the focus of an 
early EURORDIS report2 plus an additional seven conditions explicitly named in the 
UK Strategy for Rare Diseases1 (sickle cell anaemia, spina bifida, phenylketonuria, 
congenital hypothyroidism, medium chain acyl-CoA dehydrogenase deficiency, long 
QT syndrome and infantile epilepsy) were added to the search strategy as ‘tracer’ 
conditions. However, study eligibility was not limited to these 15 conditions. 
In addition, institutional repositories of key organisations concerned with rare diseases 
will also be searched, as well as contacting key experts, screening the references of 
included studies and screening studies previously known to the authors. 
Screening and Data Extraction
After de-duplication, the titles and abstracts of a random 10% of retrieved articles will 
be independently dual screened by two members of the review team using EPPI-
Reviewer software. Differences in screening outcome will be reconciled through 
discussion and mutual agreement between the two screeners with reference to 
the study inclusion criteria, with input from the third reviewer if needed to solve any 
outstanding disagreements. Following reconciliation, the remaining abstracts will be 
screened by a single reviewer. The full text of the remaining eligible articles will then 
be screened in a similar manner, with 10% dual screened and the remainder single 
screened following reconciliation. 
Data will be extracted by a single reviewer and checked for accuracy by a second. 
Data will be extracted on: 2 Eurordis. Survey of the delay in 
diagnosis for 8 rare diseases in 
Europe (’Eurordiscare 2’). 2009. 
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 • study characteristics;
 • rare disease investigated;
 • population sampled, including sampling method and sampling frame used;
 • Definition of time to diagnosis, including how this definition is operationalised within 
data collection instruments;
 • Data collection method, including whether routine data is used;
 • Data analysis method;
 • Findings and key conclusions;
 • Author-specified methodological limitations.
Synthesis and Quality Appraisal
A narrative synthesis will be followed. Given the heterogeneity of the diseases 
included and the focus on research methods rather than findings, it is not expected 
that an additional meta-analysis will be appropriate. 
As the primary aim of this review is to synthesise research and data collection 
methods rather than their results, quality appraisal is seen as an integral component 
of the synthesis and discussion rather than a standalone process. Quality appraisal 
will be entirely narrative and no formal quality appraisal tool will be used, for the 
following reasons. Commonly used quality appraisal tools are designed for assessing 
effectiveness studies whereas we may include descriptive studies. Furthermore, 
quality appraisal tools primarily assess the validity of generalising the results of each 
study based on reported methods, rather than the appropriateness of the data 
collection methods themselves. Finally, the validity of a particular method may be 
different depending on the nature of the disease and diagnostic odyssey investigated. 
Therefore summarising a study’s quality using a generic scoring system will provide 
less useful information that a narrative critique. 
However, data will be extracted and reported separately for each study on their 
choice of study methods, author-identified and reviewer-identified limitations with a 
particular focus on potential biases resulting from: participant sampling and sampling 
frame, data collection instruments, conceptual definitions of time to diagnosis and 
statistical analysis techniques. 
Two subgroups will be analysed in addition to the overall synthesis: studies using 
routine data only, and studies measuring time to diagnosis as a continuous rather 
than categorical variable. 
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Database search strategies
# Concept Search terms Hits (11/9/14) Notes
1 Key focus of 
review
diagnostic odyssey.mp 71 Included 
without further 
filters
2 Rare disease Exp Rare Diseases/ 24431 [MeSH] 
introduced 
2003
3 Rare disease?.mp 49980
4 Orphan disease?.mp 1235
5 ((rare or orphan or low prevalence or low incidence or uncommon 
or infrequent) adj1 (disease? or illness$ or condition?)).mp
85313
6 Or/2-5 85313
7 Tracer 
conditions
exp crohn disease/ or exp cystic fibrosis/ or exp Muscular 
Dystrophy, Duchenne/ or exp Ehlers-Danlos Syndrome/ or exp 
Marfan syndrome/ or exp Prader-Willi Syndrome/ or exp Tuberous 
Sclerosis/ or exp Fragile X Syndrome/
222245 Diseases 
included in 
Eurordiscare 
rare diseases 
survey
8 (crohn or crohn's or cystic fibrosis or duchenne or duchenne's or 
Ehlers-Danlos or marfan or marfan's or prader willi or tuberous 
sclerosis or fragile X).mp
280105 Conditions 
spec. 
mentioned 
in Ch3/4 
of UKRDS 
re: early 
detection/ 
diagnosis
9 Anemia, Sickle Cell/ or exp Spinal Dysraphism/ or exp 
Phenylketonurias/ or exp Congenital Hypothyroidism/ or exp Lipid 
Metabolism, Inborn Errors/ or exp Long QT Syndrome/  or exp 
Spasms, Infantile/
356880
10 (Sickle cell or spina bifida or phenylkenoturia or congenital 
hypothyroidism or medium chain acyl-CoA dehydrogenase 
deficiency or MCADD or MCAD or long QT syndrome or infantile 
epilepsy).mp
94337
11 Or/6-9 655274
12 Diagnostic 
odyssey
Exp delayed diagnosis/ 8363
13 ((odyssey? or late or delay$ or prolong$ or long or interval) adj3 
(diagnos$ or identif$) or time to diagnosis or lag-time or symptom 
interval or patient interval).mp
140960
14 ((onset or start$ or duration) adj3 (symptom? or disease or 
condition or illness)) adj7 diagnos$.mp
17770
15 Or/22-24 155723
16 RD + DO 6 and 15 2745
17 (RD or 
Tracer) + DO
(6 or 11) and 15 8824
18 OECD exp Australia/ or New Zealand/ or exp Japan/ or korea/ or 
“republic of korea”/ or Austria/ or Belgium/ or Czech Republic/ 
or exp Scandinavia/ or Estonia/ or Finland/ or exp France/ or exp 
Germany/ or Greece/ or Hungary/ or Iceland/ or Ireland/ or exp 
Italy/ or Luxembourg/or Netherlands/ or Poland/ or Portugal/ 
or Slovakia/ or Slovenia/ or Spain/ or Switzerland/ or exp Great 
Britain/ or Israel/ or exp Canada/ or exp United States/
4795730
Medline and Embase:
Diagnostic odyssey for rare diseases: exploration of potential indicators
34
# Concept Search terms Hits (11/9/14) Notes
19 OECD Australia or new Zealand or japan or austria or belgium or (korea 
not ((democratic adj3 korea) or north korea)) or czech republic or 
(scandinavia or denmark or norway or Sweden) or estonia or finland 
or france or germany or greece or hungary or Iceland or (ireland or 
eire) or italy or luxembourg or (netherlands or holland) or poland or 
portugal or (slovakia or slovak republic) or slovenia or (spain or balearic 
islands or canary islands) or switzerland or (great britain or GBR or 
united kingdom or UK or england or scotland or wales or northern 
ireland or channel islands or isle of man) or israel or canada or ((united 
states adj2 america) or united states or USA) or (oecd countr* or 
“Organisation for Economic Co-operation and Development”).mp.
6337110
20 Or/28-29 6772971
21 RD + DO + 
OECD
6 and 15 and 20 416
22 (RD or 
Tracer) + DO 
+ OECD
(6 or 11) and 15 and 20 1582
23 Study design/
article type
Exp Case-Control Studies/ or Control Groups/ or Matched-Pair 
Analysis/ or ((case* adj5 control*) or (case adj3 comparison*) or 
control group*).ti,ab or case control.tw
1619423
24 cohort studies/ or longitudinal studies/ or follow-up studies/ or 
prospective studies/ or retrospective studies/ or cohort.ti,ab. or 
longitudinal.tw or prospective.ti,ab or retrospective.tw or (cohort adj 
(study or studies)).tw or Cohort analy$.tw or (Follow up adj (study 
or studies)).tw
3822380
25 Cross-Sectional Studies/ or cross-sectional.ti,ab. or ("prevalence 
study" or "incidence study" or "prevalence studies" or "incidence 
studies" or "transversal studies" or "transversal study").ti,ab.
518045
26 "clinical trial".pt. or "clinical trial, phase i".pt. or "clinical trial, phase ii".
pt. or clinical trial, phase iii.pt. or clinical trial, phase iv.pt. or controlled 
clinical trial.pt. or "multicenter study".pt. or "randomized controlled 
trial".pt. or double-blind method/ or clinical trials as topic/ or clinical 
trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical 
trials, phase iii as topic/ or clinical trials, phase iv as topic/ or controlled 
clinical trials as topic/ or randomized controlled trials as topic/ or early 
termination of clinical trials as topic/ or multicenter studies as topic/ or 
((randomi?ed adj7 trial*) or (controlled adj3 trial*) or (clinical adj2 trial*) or 
((single or doubl* or tripl* or treb*) and (blind* or mask*))).ti,ab.
1895823
27 Epidemiologic Studies/ or (observational adj (study or studies)).tw 271211
28 Intervention$ or control$ or evaluat$ or effect?.tw 18567518
29 Or/23-28 20655421
30 Animals/ 6984680
31 Humans/ 28685331
32 30 not (30 and 31) 5104444
33 (News or comment or editorial).pt 1460015
34 comment on.cm 602974
35 29 not (32 or 33 or 34) 18231468
Medline and Embase:
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# Concept Search terms Hits (11/9/14) Notes
36 RD + DO 
+ OECD + 
design
29 not (32 or 33 or 34)
(6 and 15 and 20 and 35) or 1
318 Embase – 204
Medline – 114
37 RD or Tracer) 
+ DO + 
OECD + 
design
((6 or 11) and 15 and 20 and 35) or 1 1207 Embase – 848
Medline - 359
Medline and Embase:
# Concept Search terms Hits (8/9/14)
1 Key focus of 
review
diagnostic odyssey.mp. 1
2 Rare disease Rare disease?.mp. 304
3 Orphan disease?.mp. 17
4 ((rare or orphan or low prevalence or low incidence or uncommon or infrequent) adj1 
(disease? or illness$ or condition?)).mp.
740
5 or/2-4 740
6 Tracer 
conditions
exp cystic fibrosis/ or exp Muscular disorders/ or exp Prader Willi Syndrome/ 
or exp Fragile X Syndrome/
7875
7 (crohn or crohn's or cystic fibrosis or duchenne or duchenne's or Ehlers-Danlos or 
marfan or marfan's or prader willi or tuberous sclerosis or fragile X).mp.
4198
8 exp Sickle Cell Disease/ or exp Spina Bifida/ or exp Phenylketonuria/ or exp Lipid 
Metabolism Disorders/
1867
9 (Sickle cell or spina bifida or phenylkenoturia or congenital hypothyroidism or 
medium chain acyl-CoA dehydrogenase deficiency or MCADD or mcad or long QT 
syndrome or infantile epilepsy).mp.
2081
10 or/6-9 12207
11 Diagnostic 
odyssey
((odyssey? or late or delay$ or prolong$ or long or interval) adj3 (diagnos$ 
or identif$) or time to diagnosis or lag-time or symptom interval or patient 
interval).mp
3574
12 ((onset or start$ or duration) adj3 (symptom? or disease or condition or illness)) adj7 
diagnos$.mp
438
13 or/11-12 3940
14 (5 and 13) or 1 13
15 ((5 or 10) and 13) or 1 96
PsychINFO:
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 d
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 m
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t m
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at
ie
nt
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en
 b
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th
e 
m
et
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ol
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 s
er
vi
ce
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er
e 
no
t 
di
ag
no
se
d 
w
ith
 a
 m
et
ab
ol
ic
 
di
se
as
e.
 O
f t
he
 4
2 
in
 w
ho
m
 a
di
ag
no
si
s 
of
 g
en
et
ic
 m
et
ab
ol
ic
 
di
se
as
e 
w
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 c
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fir
m
ed
, 3
4 
(8
1%
) w
er
e 
di
ag
no
se
d 
w
ith
in
 
on
e 
m
on
th
 o
f p
re
se
nt
in
g 
to
 a
 
m
et
ab
ol
ic
 s
pe
ci
al
is
t; 
in
 a
no
th
er
 
fiv
e 
ca
se
s 
(1
2%
), 
th
e 
di
ag
no
si
s 
w
as
 e
st
ab
lis
he
d 
w
ith
in
 1
–3
 
m
on
th
s 
an
d 
in
 o
ne
 c
as
e 
(2
%
), 
it 
w
as
 e
st
ab
lis
he
d 
in
 3
–6
 m
on
th
s.
 
In
 tw
o 
ca
se
s 
(5
%
), 
di
ag
no
si
s 
w
as
 
es
ta
bl
is
he
d 
ov
er
 6
 m
on
th
s 
af
te
r 
pr
es
en
ta
tio
n.
W
he
n 
a 
di
ag
no
si
sw
as
 a
ct
ua
lly
 
po
ss
ib
le
, i
t w
as
 g
en
er
al
ly
 m
ad
e 
w
ith
in
 o
ne
 m
on
th
 o
f b
ei
ng
 
se
en
 b
y 
th
e 
ge
ne
tic
 m
et
ab
ol
ic
 
co
ns
ul
ta
nt
. I
n 
th
os
e 
ca
se
s
w
he
re
 te
st
in
g 
di
d 
no
t r
ev
ea
l a
di
ag
no
si
s 
w
ith
in
 3
 m
on
th
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 a
 
di
ag
no
si
s 
w
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 ra
re
ly
 m
ad
e.
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t
Th
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m
ed
ia
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tim
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la
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fro
m
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t
sy
m
pt
om
 to
 fi
rs
t v
is
it 
to
 a
 m
ed
ic
al
pr
ac
tit
io
ne
r w
as
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 w
ee
ks
 (r
an
ge
0–
24
w
ks
; m
ea
n 
3.
7w
ks
; S
D
 
3.
8w
ks
). 
It 
w
as
 s
ho
rt
er
 fo
r t
ho
se
 
w
ho
 h
ad
 p
re
vi
ou
sl
y 
ex
hi
bi
te
d 
no
rm
al
 d
ev
el
op
m
en
t t
ha
n 
fo
r 
th
os
e 
w
ith
 p
sy
ch
om
ot
or
 d
el
ay
 
(p
=
0.
02
8)
. T
he
 ti
m
e 
la
g 
fro
m
 fi
rs
t 
vi
si
t t
o 
di
ag
no
si
s 
an
d 
in
iti
at
io
n 
of
 
tre
at
m
en
t (
m
ed
ia
n 
2w
ks
; m
ea
n 
4.
8w
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, S
D
 7
.3
w
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; r
an
ge
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36
w
ks
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ho
rt
er
 fo
r t
ho
se
pr
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en
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g 
to
 p
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(3
.7
w
ks
) t
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ho
se
pr
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pr
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 d
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 d
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4 
w
ee
ks
 w
ith
 a
 
pe
ak
 a
t 4
 w
ee
ks
 (F
ig
. 2
). 
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 m
on
th
 o
f t
he
 fi
rs
t 
sy
m
pt
om
s 
in
 7
8 
in
fa
nt
s 
(4
9%
) 
an
d 
w
ith
in
 th
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 re
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 m
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t d
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: m
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ye
ar
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 m
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ar
s)
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, d
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tic
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 m
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ag
no
se
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ar
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 c
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tim
e 
be
tw
ee
n 
sy
m
pt
om
 o
ns
et
 a
nd
 d
ia
gn
os
is
 
w
as
 2
 y
ea
rs
 (I
Q
R
 0
.3
3,
 6
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in
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4.
7%
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ed
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n 
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m
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te
 
di
ag
no
si
s 
(T
tD
 =
 0
) o
f M
ar
fa
n 
S
yn
dr
om
e 
an
d 
th
e 
re
m
ai
ni
ng
21
5 
in
su
re
rs
 (5
5.
3%
) w
er
e 
di
ag
no
se
d 
af
te
r 
a 
tim
e 
pe
rio
d 
gr
ea
te
r 
th
an
 0
 d
ay
s,
 w
ith
 a
n 
av
er
ag
e 
tim
e 
to
 d
ia
gn
os
is
 o
f
60
7 
da
ys
, a
 m
ed
ia
n 
of
 6
41
 d
ay
s,
 
an
d 
a 
m
ax
im
um
 o
f 1
09
5 
da
ys
.
Th
e 
qu
an
tit
y 
of
 p
hy
si
ci
an
s 
an
d 
th
e 
ne
ar
es
t a
va
ila
bl
e 
he
al
th
 c
ar
e 
ce
nt
er
 d
o 
no
t p
la
y 
an
 im
po
rt
an
t 
ro
le
 in
 d
et
er
m
in
in
g 
th
e 
pr
ob
ab
ilit
y 
of
 a
n 
im
m
ed
ia
te
 d
ia
gn
os
is
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r 
M
ar
fa
n 
S
yn
dr
om
e.
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ge
 a
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al
 to
 th
e
do
ct
or
 fo
r 
sp
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he
ni
c
sy
m
pt
om
s
A
ge
 a
t o
rig
in
al
di
ag
no
si
s
Th
er
e 
w
as
 re
la
tiv
el
y 
m
or
e 
m
en
 
(n
 =
 1
2;
 9
2%
) t
ha
n 
w
om
en
 (n
 =
 
36
; 6
8%
) w
ho
se
 d
ia
gn
os
is
 w
as
 
es
ta
bl
is
he
d 
w
ith
in
 1
 y
ea
r f
ro
m
 th
e 
tim
e 
of
 re
fe
rr
al
 to
 th
e 
ph
ys
ic
ia
n 
(|z
| 
= 
2.
49
, P
 =
 0
.0
13
). 
In
 a
ll w
om
en
 
w
ith
 n
on
-c
on
fir
m
ed
 M
G
 th
e
di
ag
no
si
s 
w
as
 e
st
ab
lis
he
d 
w
ith
in
 1
 
ye
ar
 fr
om
 re
fe
rr
al
 to
 th
e 
ph
ys
ic
ia
n,
 
w
he
re
as
 6
8%
 o
f w
om
en
 w
ith
 
co
nfi
rm
ed
 M
G
 re
ce
iv
ed
 th
e 
di
ag
no
si
s 
w
ith
in
 1
 y
ea
r (
|z
| =
 5
.0
0,
 
P
 <
 0
.0
00
1)
. R
el
at
iv
el
y 
m
or
e 
w
om
en
 w
ith
 n
on
co
nfi
rm
ed
 M
G
 
(n
 =
 1
1;
 9
2%
) h
ad
 a
n 
es
ta
bl
is
he
d 
di
ag
no
si
s 
w
ith
in
 1
 y
ea
r a
fte
r o
ns
et
 
of
 s
ym
pt
om
s 
th
an
 w
om
en
w
ith
 c
on
fir
m
ed
 M
G
 (n
 =
 2
9;
 5
5%
) 
(|z
| =
 3
.5
2,
 P
 <
 0
.0
00
5)
. T
he
 
op
po
si
te
 w
as
 tr
ue
 fo
r m
en
 a
nd
 
th
e 
di
ffe
re
nc
e 
be
ca
m
e 
si
gn
ifi
ca
nt
 
at
 1
8 
m
on
th
s,
 a
t a
 ti
m
e 
w
he
n 
th
e 
di
ag
no
si
s 
w
as
 e
st
ab
lis
he
d 
in
 1
1 
m
en
 w
ith
 c
on
fir
m
ed
 M
G
 (8
5%
) 
co
m
pa
re
d 
to
 th
re
e 
(4
3%
) w
ith
 
no
n-
co
nfi
rm
ed
 M
G
 (|
z|
 =
 1
.9
7,
 
P
 =
 0
.0
49
).
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A
ve
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ge
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f o
ns
et
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sy
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w
as
 s
ig
ni
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an
tly
 
gr
ea
te
r 
in
 D
M
2 
m
em
be
rs
(3
4.
0 
±
 1
4.
1 
ye
ar
s)
 c
om
pa
re
d 
to
 D
M
1 
m
em
be
rs
 (2
6.
1 
±
 1
3.
2 
ye
ar
s;
 p
<
0.
00
01
). 
D
M
 m
em
be
rs
 
w
ith
 in
iti
al
 s
ym
pt
om
s 
re
po
rt
ed
 
be
fo
re
 a
ge
 1
8 
ye
ar
s 
ha
d 
gr
ea
te
r
di
ag
no
st
ic
 d
el
ay
 (1
3.
0 
±
 1
1.
3 
ye
ar
s)
 c
om
pa
re
d 
to
 m
em
be
rs
w
ith
 o
ns
et
 a
fte
r 
ag
e 
18
 y
ea
rs
 
(d
el
ay
s 
of
 6
.9
 ±
 8
.2
 y
ea
rs
; 
p<
0.
00
01
).
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Appendix 4 Interview participants
Name Position Organisation
Robin Lachmann Consultant in Metabolic Medicine Univeristy College London Hospital
Hywel Williams Senior Research Associate, Centre for 
Translational Research, Genetics and 
Genomic Medicine 
Institute of Child Health, London
Jim Bonham Clinical Director of Diagnostics, 
Pharmacy & Genetics
Sheffield Children's NHS Foundation 
Trust
Fiona Stewart Consultant in Genetic Medicine Belfast City Hospital
Liam Smeeth Professor of Clinical Epidemiology/
General Practitioner
London School of Hygiene and Tropical 
Medicine
Mark Bale
Colin Pavelin
Melanie Peffer
Deputy Director of Health Science & 
Bioethics
Head of Genomics and Rare Diseases 
Programme
Policy Manager Genomics, Science 
and Emerging Technologies
Department of Health
Health Education England
Department of Health
Iain Mellis Accountable commissioner – 
Metabolic Diseases
NHS England
Edmund Jessop Specialist Commissioner NHS England
Jacquie Westwood
Jane Deller
Director
Programme Manager
UK Genetic Testing Network
Lara Bloom Chief Operations Officer Ehlers-Danlos Syndrome UK
Tess Harris Chief Executive Polycystic Kidney Disease Charity
Jayne Spink Chief Executive Officer Tuberous Sclerosis Association
Graham Lipkin Consultant Nephrologist/Lead at Rare 
Diseases Centre
Institute for Translational Medicine, 
Queen Elizabeth Hospital Birmingham
David Goldblatt Director of Clinical Research and 
Innovation, Academic Lead for future 
Centre for Rare Diseases
Institute of Child Health, London
Sarah Stevens Public Health Consultant
National Disease Registration
Public Health England
Dirk Demuth
Paola Nasuti
Lara Lucchese
Clinical Project Director
Senior Consultant
Senior Consultant
IMS Health
Willie Hamilton Professor of Primary Care Diagnostics University of Exeter Medical School
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Appendix 5 
Interview topic 
guide
Adapted to suit each 
interviewee and in 
response to themes 
emerging from previous 
interviews. 
Start of interview: Thanks, consent, introduction and presentation of study aim 
Topic questions (to be adapted to the particular interviewee and in response to the 
flow of discussion during the interview):
 • What is your day to day interaction/experience with people with rare diseases?
 • What for you are the key issues around diagnostic odysseys/delayed diagnosis in 
rare diseases?
 • What are the key causes/contributors to these delays?
 • When do you consider to be the start of a diagnostic odyssey?
 • When do you consider a diagnostic odyssey to have ended?
 • What would be the best way of capturing data on time to diagnosis in rare 
diseases? Do you know of any existing data? 
 • What rare diseases would it be reasonable to generalise across in terms of 
changes to time to diagnosis? Are there any particular categories of rare disease 
that we should consider?
 • Given the impossibility of analysing all 6000 rare diseases, we have considered 
selecting a small number of tracer conditions to focus on. Are there any conditions 
that you feel would be particularly important to include or exclude? What criteria 
would be sensible to use to select tracer conditions?
 • How meaningful would it be to collect data on all patients with rare diseases that 
are admitted/seen at/tested at a particular facility that commonly manages people 
with rare diseases? 
End of interview: is there anything else you think I should know about diagnostic 
odysseys in rare diseases? Thank you for your time and insights. 
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Appendix 7 Presenting symptoms for rare diseases previously used to 
measure time to diagnosis
Disease Presenting symptoms indicative of start of diagnostic odyssey
Alpha1-antitrypsin deficiency1 Age at onset of respiratory complaints: Mostly dyspnoea and non-productive cough, also 
cough with sputum, dyspnoea at rest and paroxysmal dyspnoea.
Batten Disease/neuronal 
ceroid lipofuscinosis2
Motor deterioration, visual deterioration, first seizure noted
Bronchiectasis3 Age at onset of cough
Cerebrotendinous 
xanthomatosis4
Age at first neurological symptom/presenting symptom: Symptoms found at presentation 
generally neurological (mental retardation most common), also a history of chronic 
diarrhoea or juvenile cataracts
Congenital Dyserythropoietic 
Anemia Type5
Onset of anaemia
Congenital Hypothyroidism6 Most frequent symptoms found were obstructive constipation, lethargy and feeding 
difficulties
Duchenne muscular 
dystrophy7
First parental concerns: most common symptoms waddling gait, difficulty with steps, falls, 
delayed motor development, speech delay
Dystonia or hemifacial spasm8 Age at onset of movement disorders
Fabry disease9, 10 Ramaswami et al (2006): Clinical manifestions categorised into neurological, 
gastrointestinal, ophthalmological, auditory, dermatological and 'various'
Andrikos et al (2010): presenting symptoms included Angiokeratomas,
Abdominal pain-Diarrhea, Hypohidrosis, Lymphedema, Pain crises, Acroparesthesias, 
Hypohidrosis, Hearing loss, Cold-Heat Intolerance, Arthritis, Lymphedema
Fragile X11 Initial concern about development expressed by someone/diagnosis of developmental 
delay made: ascertained during interview by asking ‘How did you first learn about fragile X 
syndrome?’
Gastric Cancer12 Named codes for gastric cancer-related symptoms: benign neoplasm of other and ill-
defined parts of digestive system (stomach); neoplasm of uncertain or unknown behaviour 
of oral cavity and digestive organs (stomach); oesophagitis; special screening
GM2 gangliosidosis13 Symptoms cited included developmental delay or regression, strabismus or perceived 
visual impairment and hyperacusis
Haemophilia14 Attendance to a doctor with bleeding, bruising or joint pain
Lymphangioleiomyomatosis15 First lung-related symptom: included dyspnoea, cough, pneumothorax, pleural effusions.
Marfan Syndrome16 Named symptom codes: constitutional tall stature, other disorders of lens, astigmatism, 
floppy mitral valve syndrome, non-rheumatic aortic valve disorders, endocarditis
Myotonic dystrophy17 6 symptoms based on 'core manifestations' of MD and 'high impact on quality of life': 
mytonia, weakness, cataracts, pain, fatigue, sleep disturbances
Niemann-Pick type C18 First neurological symptom: questionnaire with 270 questions on medical history
Primary myoclonus-dystonia19 myoclonus or dystonia
Takayasu arteritis20 Onset of first symptom, categorised as: vascular, cardiac, CNS, Musculoskeletal, 
Constitutional and Laboratory.
West syndrome21 Beginning of spasms. Identification on structural lesions of the brain or a genetic disorder 
was considered a ‘symptom’.
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